The biotech is clearly innovative, but sometimes that's not enough.

fool.com - 2026-07-08 18:45:00

Heartflow leverages AI-enabled software to dominate the non-invasive coronary diagnostic market, backed by a stable base of over 1,450 accounts. Iovance Biotherapeutics is pioneering personalized TIL therapies for cancer, backed by centralized manufacturing and significant revenue growth from its lead products.

fool.com - 2026-07-04 09:44:59

Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers.

fool.com - 2026-06-23 19:33:07

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance's common stock to twenty-seven new, non-executive employees.

globenewswire.com - 2026-06-19 17:15:00

IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC, endometrial, sarcoma) and global markets underpins the pipeline-in-a-drug thesis. A more receptive FDA increases the likelihood of accelerated approvals based on single-arm data, streamlining IOVA's development path.

seekingalpha.com - 2026-06-17 11:31:00

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy

globenewswire.com - 2026-06-03 16:05:00

Iovance Biotherapeutics has surged over the past year, but the stock is down by nearly 80% over the past five years. Past issues with dilution and disappointment may be clearing up, given recent sales growth and the company's current cash position.

fool.com - 2026-06-02 00:15:00

Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug application for IOV-5001, extending its next-generation cell therapy platform into solid tumors the company said account for more than 100,000 US deaths a year. The clearance allows Iovance to begin clinical work on IOV-5001 and marks the platform's move beyond its current focus and into the solid tumor setting.

proactiveinvestors.com - 2026-06-01 12:32:25

Iovance Biotherapeutics (NASDAQ:IOVA) said it has obtained clearance of an Investigational New Drug application for IOV-5001, extending its next-generation...

proactiveinvestors.com - 2026-06-01 08:29:00

Next-Generation Platform Expands into Solid Tumors  Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced allowance to proceed from the U.S. Food and Drug Administration (FDA) for the investigational new drug (IND) application for a Phase 1/2 basket trial of IOV-5001, a next-generation interleukin-12 (IL-12) tethered TIL therapy.

globenewswire.com - 2026-06-01 07:30:00

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

zacks.com - 2026-05-28 11:50:34

SAN CARLOS, Calif. , May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on May 21, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 93,340 shares of Iovance's common stock to thirteen new, non-executive employees.

globenewswire.com - 2026-05-22 17:15:00

SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 21, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 93,340 shares of Iovance's common stock to thirteen new, non-executive employees.

globenewswire.com - 2026-05-22 17:15:00

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Fred Vogt, PhD, Interim CEO, President and General Counsel, and Corleen Roche, Chief Financial Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York, NY.

globenewswire.com - 2026-05-21 08:05:00

SAN CARLOS, Calif. , May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Fred Vogt, PhD, Interim CEO, President and General Counsel, and Corleen Roche, Chief Financial Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.

globenewswire.com - 2026-05-21 08:05:00

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

zacks.com - 2026-05-08 12:11:09

Iovance Biotherapeutics, Inc. markets Amtagvi, a TIL therapy for advanced melanoma, and just reported Q1 earnings. Following Q1 results, IOVA shares declined over 13%, closing at $3.55, with a market cap of $1.59bn. The earnings announcement triggered a notable sell-off, reflecting investor concerns about near-term performance.

seekingalpha.com - 2026-05-08 10:58:39

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 17:21:16

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.19 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.

zacks.com - 2026-05-07 09:56:04

1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates.

globenewswire.com - 2026-05-07 07:05:00

It could just as well drop by 50% -- or more -- over the next 12 months.

fool.com - 2026-05-02 02:30:00

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:01:42

Iovance Biotherapeutics is rated a BUY following Replimune's exit, solidifying IOVA's lead in post-PD-1 melanoma. IOVA's lifileucel shows best-in-class ORR in earlier-line melanoma and promising efficacy in NSCLC, with a strong clinical pipeline and upcoming catalysts. Commercial ramp of lifileucel is underway, with 2025 sales at $220M and gross margins improving to 50%, but operational and adoption hurdles persist.

seekingalpha.com - 2026-04-28 11:27:33

SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, May 7, 2026 at 8:30 a.m. ET to report its first quarter 2026 financial results and corporate updates.

globenewswire.com - 2026-04-27 08:01:00

SAN CARLOS, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on April 16, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 135,470 shares of Iovance's common stock to twelve new, non-executive employees.

globenewswire.com - 2026-04-17 17:15:00